Drug Trial Radar · NCT03299166
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
426
Actual
Start
Dec 19, 2017
Primary completion
Jun 2, 2020
Study completion Dec 8, 2025
Sponsor
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment
Conditions
- Obsessive-Compulsive Disorder
Interventions
TroriluzoleDrug
Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
PlaceboDrug
Matching capsule once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total ScoreTime frame: Baseline, Week 12
Locations
57 sites in 1 country. Site status is shown where the registry gives one.
Metropolitan Neuro Behavioral Institute
Chandler, Arizona
Preferred Research Partners, Inc.
Little Rock, Arkansas
Collaborative Neuroscience Network, LLC
Garden Grove, California
University of California San Diego
La Jolla, California
Synergy Research San Diego
Lemon Grove, California
CalNeuro Research Group
Los Angeles, California
Pacific Research Partners, LLC
Oakland, California
NRC Research Institute
Orange, California
Desert Valley Research
Rancho Mirage, California
Artemis Institute for Clinical Research
San Diego, California
Artemis Institute for Clinical Research
San Marcos, California
Stanford University, Department of Psychiatry and Behavioral Sciences
Stanford, California
Pacific Clinical Research Medical Group
Upland, California
Mountain View Clinical Research, Inc.
Denver, Colorado
Institute of Living / Hartford Hospital
Hartford, Connecticut
Yale University
New Haven, Connecticut
Comprehensive Psychiatric Care
Norwich, Connecticut
Gulfcoast Clinical Research Center
Fort Myers, Florida
University of Florida Department of Psychiatry
Gainesville, Florida
Galiz Research
Hialeah, Florida
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida
SIH Research, Inc
Kissimmee, Florida
Harmony Clinical Research
North Miami Beach, Florida
Medical Research Group of Central Florida
Orange City, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
iResearch Atlanta, LLC
Decatur, Georgia
iResearch Savannah
Savannah, Georgia
Chicago Research Center
Chicago, Illinois
University of Chicago Department of Psychiatry & Behavioral Neuroscience
Chicago, Illinois
AMR-Baber Research, Inc
Naperville, Illinois
Phoenix Medical Research, Inc.
Prairie Village, Kansas
Heartland Research Associates, LLC
Wichita, Kansas
Pharmasite Research, Inc.
Pikesville, Maryland
McLean Hospital
Belmont, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Boston Clinical Trials
Boston, Massachusetts
Michigan Clinical Research PC
Ann Arbor, Michigan
Precise Research Centers
Flowood, Mississippi
ActivMed Practices and Research, Inc.
Portsmouth, New Hampshire
Center for Emotional Fitness
Cherry Hill, New Jersey
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.